Effects of treatment with janus kinase inhibitors on coronary microvascular perfusion in patients with rheumatoid arthritis: an observational prospective cohort study
Anyfanti, Panagiota Angeloudi, Eleni Pagkopoulou, Eleni Boutel, Maria Moysidou, Georgia-Savina Deuteraiou, Kleopatra Bekiari, Eleni Doumas, Michael Kitas, George D Dimitroulas, Theodoros
Anyfanti, Panagiota
Angeloudi, Eleni
Pagkopoulou, Eleni
Boutel, Maria
Moysidou, Georgia-Savina
Deuteraiou, Kleopatra
Bekiari, Eleni
Doumas, Michael
Kitas, George D
Dimitroulas, Theodoros
Affiliation
Aristtle University of Thessaloniki; National and Kapodistrain University of Athens Medical School; The Dudley Group NHS Foundation Trust
Other Contributors
Publication date
2025-04-19
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Despite their increasing use and their proven efficacy in the treatment of rheumatoid arthritis (RA), Janus kinase (JAK) inhibitors have been questioned by credible cardiovascular safety concerns. To date, mechanistic links of cardiovascular complications to JAK inhibitors remain largely unexplored. We aimed to investigate the effect of JAK inhibition on coronary microvascular blood flow in a previously published cohort of treated patients with RA. We prospectively enrolled RA patients initiating treatment with JAK inhibitors. Study procedures were performed at baseline and repeated 3 months after treatment. Patients underwent applanation tonometry in the radial artery to assess subendocardial viability ratio (SEVR) otherwise known as Buckberg index, a noninvasive marker of myocardial perfusion. Thirteen patients with RA were enrolled, of whom 11 completed the study. All patients presented with at least one cardiovascular risk factor (e.g., age ? 65 years, history of current or past smoking, obesity, hypertension). No change in other than antirheumatic treatment was performed during the study, and no significant changes were observed in baseline characteristics other than triglyceride levels. Compared to baseline, three months treatment with JAK inhibitors did not significantly alter SEVR values [126 (102-144) % vs. 134 (106-251) %, p = 0.083]. Three months treatment with JAK inhibitors did not seem to significantly affect myocardial perfusion in a small RA cohort with cardiovascular risk factors, who would be presumably more vulnerable to adverse treatment-related cardiovascular effects. Larger studies with longer follow-up are needed to document the effects of JAK inhibitors on the myocardium.
Citation
Anyfanti P, Angeloudi E, Pagkopoulou E, Boutel M, Moysidou GS, Deuteraiou K, Bekiari E, Doumas M, Kitas GD, Dimitroulas T. Effects of treatment with janus kinase inhibitors on coronary microvascular perfusion in patients with rheumatoid arthritis: an observational prospective cohort study. Rheumatol Int. 2025 Apr 19;45(5):111. doi: 10.1007/s00296-025-05862-y.